Citius Pharmaceuticals Inc

CTXR

Company Profile

  • Business description

    Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

  • Contact

    11 Commerce Drive
    First Floor
    CranfordNJ07016
    USA

    T: +1 908 967-6677

    E: [email protected]

    https://www.citiuspharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2026

    Employees

    23

Stocks News & Analysis

stocks

2 ASX shares that benefit from sticky inflation

Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks

Our view of Dexus / Scentre deal

Dexus acquires stake in Westfiend Chermside.
stocks

Undervalued ASX retailer benefiting from rebound in spending

Uplift in sales momentum continues.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,874.2025.800.29%
CAC 408,100.905.26-0.06%
DAX 4024,097.1120.240.08%
Dow JONES (US)48,114.26302.30-0.62%
FTSE 1009,842.70157.911.63%
HKSE25,468.78233.370.92%
NASDAQ23,111.4654.050.23%
Nikkei 22549,512.28128.990.26%
NZX 50 Index13,295.91129.04-0.96%
S&P 5006,800.2616.25-0.24%
S&P/ASX 2008,585.2021.600.25%
SSE Composite Index3,870.2845.471.19%

Market Movers